Can care delivery and payment reform in healthcare help tide us over the existing gaps in cancer care?
How would healthcare reform impact cancer care delivery and reimbursement? Will value-based models push for a more integrated and ideal care delivery for oncology patients?
Rebekkah Schear, MIA, thinks that the Oncology Care Model (OCM) is a good start and its impact will become clear over time. However, she does expect to see a positive impact on navigation care planning, with the patient at the center of the process. “We are moving from “an illness-centered perspective toward a person-centered perspective,” Schear said.
Michael Kolodziej, MD, said that he too, is looking forward to learning what implementation of the OCM will do, as data would be scrutinized for quality and process improvement while keeping the patient front and center. “The idea that you do things because this is the way we do things, and the patient’s kind of peripheral to all this, that’s disappearing,” he added.
"I think what we're seeing, and I hope will continue to be seen, is that patient centeredness is the point," Schear said, adding that "all opportunities moving forward to help patients and families sort of articulate our humanity and fore care systems evolve towards supporting patients in their individuality and to really look at holistic healing—healing's in the perspective of this multidimensional place and looking at people."
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More
Makers of medical tests will have about 4 years to show the FDA that their new offerings deliver accurate results; after previously decreasing for 27 years, US tuberculosis (TB) cases increased every year since 2020; a US district judge rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to the Medicare drug price negotiation program.
Read More